SCHEMBL24722155

SCHEMBL24722155

CN(CC(=O)O)C(=O)c1ccc(N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HIF1A Q16665 1/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
PHLPP2 Q6ZVD8 1/20 0.44
ITGB3 P05106 3/20 0.43
ITGA2B P08514 3/20 0.43
MAOA P21397 3/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PIN1 Q13526 1/20 0.38
TSHR P16473 2/20 0.38
SLC22A2 O15244 1/20 0.38
SLC22A1 O15245 1/20 0.38
ALDH1A1 P00352 1/20 0.38
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11107022 0.90 HDAC1 (0.45) MAPTKDM4EITGB3ITGA2BHDAC1
SCHEMBL12459931 0.84 LMNA (0.44) MAPTKDM4EHIF1ASLC22A6SLC22A8
SCHEMBL12302105 0.83 KMT2A (0.48) LMNAALDH1A1NPC1RAB9A
SCHEMBL2282162 0.82 KMT2A (0.53) HDAC1HDAC6PIN1ALDH1A1MLYCD
SCHEMBL3035829 0.82 PHLPP2 (0.45) MAPTKDM4EHIF1ASLC22A6SLC22A8
SCHEMBL4223718 0.81 P2RX7 (0.51) MAPTMAOACYP1A2TSHRALDH1A1
SCHEMBL25526179 0.81 LMNA (0.48) MAPTPHLPP2MAOALMNACYP1A2
Hydrochloric Acid SCHEMBL1372985 0.81 KMT2A (0.51) MAPTHDAC1HDAC6PIN1ALDH1A1
SCHEMBL10078853 0.81 MEN1 (0.41) MAPTKDM4EITGB3ITGA2BPIN1
SCHEMBL30530699 0.80 HPGD (0.59) HDAC1HDAC6ALDH1A1ACHENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259225-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use REGENERON PHARMACEUTICALS, INC. 2022-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259225-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use SLC10A1, HNMT, OGFR MAPT 3597/4885KDM4E 4593/4885HIF1A 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.